Format

Send to

Choose Destination
J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S105-11.

Etanercept: An overview.

Author information

1
Department of Dermatology, University of Washington, 515 Minor Avenue, Suite 200, Seattle, WA 98104, USA. docgoffe@msn.com

Abstract

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

PMID:
12894133
DOI:
10.1016/mjd.2003.554
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center